SRDX - Surmodics Non-GAAP EPS of -$0.13 revenue of $23M; reaffirms full year guidance

Surmodics press release (NASDAQ:SRDX): FQ1 Non-GAAP EPS of -$0.13. Revenue of $23M (+3.1% Y/Y). Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million vs. consensus of $105.00M. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25) vs. consensus of -$1.47.

For further details see:

Surmodics Non-GAAP EPS of -$0.13, revenue of $23M; reaffirms full year guidance